Glucose-sensitive insulin with attenuation of hypoglycaemia
Thomas Hoeg-Jensen,Thomas Kruse,Christian L. Brand,Jeppe Sturis,Christian Fledelius,Peter K. Nielsen,Erica Nishimura,Alice R. Madsen,Lennart Lykke,Kim S. Halskov,Simona Koščová,Vladislav Kotek,Anthony P. Davis,Robert A. Tromans,Michael Tomsett,Guillem Peñuelas-Haro,Daniel J. Leonard,Michael G. Orchard,Andy Chapman,Gaetano Invernizzi,Eva Johansson,Daniele Granata,Bo F. Hansen,Thomas A. Pedersen,Jonas Kildegaard,Karen-Margrethe Pedersen,Hanne H. F. Refsgaard,Lene Alifrangis,Johannes J. Fels,Anita V. Neutzsky-Wulff,Per Sauerberg,Rita Slaaby
DOI: https://doi.org/10.1038/s41586-024-08042-3
IF: 64.8
2024-10-17
Nature
Abstract:The risk of inducing hypoglycaemia (low blood glucose) constitutes the main challenge associated with insulin therapy for diabetes 1,2 . Insulin doses must be adjusted to ensure that blood glucose values are within the normal range, but matching insulin doses to fluctuating glucose levels is difficult because even a slightly higher insulin dose than needed can lead to a hypoglycaemic incidence, which can be anything from uncomfortable to life-threatening. It has therefore been a long-standing goal to engineer a glucose-sensitive insulin that can auto-adjust its bioactivity in a reversible manner according to ambient glucose levels to ultimately achieve better glycaemic control while lowering the risk of hypoglycaemia 3 . Here we report the design and properties of NNC2215, an insulin conjugate with bioactivity that is reversibly responsive to a glucose range relevant for diabetes, as demonstrated in vitro and in vivo. NNC2215 was engineered by conjugating a glucose-binding macrocycle 4 and a glucoside to insulin, thereby introducing a switch that can open and close in response to glucose and thereby equilibrate insulin between active and less-active conformations. The insulin receptor affinity for NNC2215 increased 3.2-fold when the glucose concentration was increased from 3 to 20 mM. In animal studies, the glucose-sensitive bioactivity of NNC2215 was demonstrated to lead to protection against hypoglycaemia while partially covering glucose excursions.
multidisciplinary sciences